文献速递眼底病与葡萄膜炎

人工智能算法用于3万例糖尿病视网膜病变筛查的前瞻性评估

Prospective evaluation of an artificial intelligence-enabled algorithm for automated diabetic retinopathy screening of 30 000 patients.
PubMed 文献 · Br J Ophthalmol · 2020-06-30

结果显示,该算法对需转诊视网膜病变的敏感性为95.7%,对高危视网膜病变敏感性达100%,特异性68%,可望将人工分级工作量减半。

要点

  • EyeArt对需转诊视网膜病变的敏感性为95.7%,对中重度非增殖期和增殖期病变敏感性均为100%。
  • 算法特异性为68%,与人工分级无视网膜病变一致;结合非转诊视网膜病变时特异性为54.0%。
  • 该算法在真实筛查场景中展现出安全的高危视网膜病变敏感性,有望减少人工分级工作量。

核心结论

  • EyeArt算法在真实世界筛查服务中对高危视网膜病变表现出安全的敏感性,其特异性可望将人工分级工作量减半。

主要发现

  • EyeArt对需转诊视网膜病变(包括人工分级不可分级、需转诊黄斑病变、中重度非增殖期或增殖期)的敏感性为95.7%(95%CI 94.8%–96.5%)。
  • 对轻度至中度非增殖期视网膜病变伴需转诊黄斑病变的敏感性为98.3%(95%CI 97.3%–98.9%)。
  • 对中重度非增殖期视网膜病变的敏感性为100%(95%CI 98.7%–100%),对增殖期病变的敏感性为100%(95%CI 97.9%–100%)。
  • 与人工分级无视网膜病变的一致率(特异性)为68%(95%CI 67%–69%),结合非转诊视网膜病变时特异性为54.0%(95%CI 53.4%–54.5%)。

临床怎么用

  • 该AI算法可用于糖尿病视网膜病变筛查中的分诊,安全识别高危病变,并可能减少人工分级工作量。
  • 在缺乏受训人员或需要大规模快速结果的场景中,此类算法可提供与人工分级临床等效的快速检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Human grading of digital images from diabetic retinopathy (DR) screening programmes represents a significant challenge, due to the increasing prevalence of diabetes. We evaluate the performance of an automated artificial intelligence (AI) algorithm to triage retinal images from the English Diabetic Eye Screening Programme (DESP) into test-positive/technical failure versus test-negative, using human grading following a standard national protocol as the reference standard. METHODS: Retinal images from 30 405 consecutive screening episodes from three English DESPs were manually graded following a standard national protocol and by an automated process with machine learning enabled software, EyeArt v2.1. Screening performance (sensitivity, specificity) and diagnostic accuracy (95% CIs) were determined using human grades as the reference standard. RESULTS: Sensitivity (95% CIs) of EyeArt was 95.7% (94.8% to 96.5%) for referable retinopathy (human graded ungradable, referable maculopathy, moderate-to-severe non-proliferative or proliferative). This comprises sensitivities of 98.3% (97.3% to 98.9%) for mild-to-moderate non-proliferative retinopathy with referable maculopathy, 100% (98.7%,100%) for moderate-to-severe non-proliferative retinopathy and 100% (97.9%,100%) for proliferative disease. EyeArt agreed with the human grade of no retinopathy (specificity) in 68% (67% to 69%), with a specificity of 54.0% (53.4% to 54.5%) when combined with non-referable retinopathy. CONCLUSION: The algorithm demonstrated safe levels of sensitivity for high-risk retinopathy in a real-world screening service, with specificity that could halve the workload for human graders. AI machine learning and deep learning algorithms such as this can provide clinically equivalent, rapid detection of retinopathy, particularly in settings where a trained workforce is unavailable or where large-scale and rapid results are needed.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Heydon P, Egan C, Bolter L, et al. Prospective evaluation of an artificial intelligence-enabled algorithm for automated diabetic retinopathy screening of 30 000 patients. Br J Ophthalmol. 2020. PMID: 32606081. doi:10.1136/bjophthalmol-2020-316594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。